{"filing":{"accession_number":"0001437749-26-027454","cik":"0001131343","ticker":"PRNAF","company_name":"ALTERITY THERAPEUTICS LTD","form":"6-K","filing_date":"2026-08-13","report_date":"2026-08-31","primary_document":"athe20260812_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1131343/000143774926027454/athe20260812_6k.htm"},"events":[{"id":27408,"run_id":24978,"accession_number":"0001437749-26-027454","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This announcement discloses the granting of a new U.S. composition of matter patent for ATH434 extending protection to at least 2045. While primarily an intellectual property milestone, the disclosure emphasizes material strategic and commercial value: it strengthens ATH434's long-term commercial potential, enables future development in Parkinson's disease, supports potential partnerships, and represents \"one of the most critical steps\" in protecting the innovation behind the company's lead clinical asset. This is a material operational/strategic event affecting the registrant's competitive position and development prospects, though it does not fit the specific categories of M\u0026A, litigation, or regulatory approval.","company_name":"ALTERITY THERAPEUTICS LTD","ticker":"PRNAF","filing_date":"2026-08-13","form":"6-K","submitted_at":null,"items":[{"id":28936,"accession_number":"0001437749-26-027454","item_number":"EX-99.1","item_title":"ex_1003419.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This announcement discloses the granting of a new U.S. composition of matter patent for ATH434 extending protection to at least 2045. While primarily an intellectual property milestone, the disclosure emphasizes material strategic and commercial value: it strengthens ATH434's long-term commercial potential, enables future development in Parkinson's disease, supports potential partnerships, and represents \"one of the most critical steps\" in protecting the innovation behind the company's lead clinical asset. This is a material operational/strategic event affecting the registrant's competitive position and development prospects, though it does not fit the specific categories of M\u0026A, litigation, or regulatory approval.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-13T10:10:51.733702+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28936,"accession_number":"0001437749-26-027454","item_number":"EX-99.1","item_title":"ex_1003419.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This announcement discloses the granting of a new U.S. composition of matter patent for ATH434 extending protection to at least 2045. While primarily an intellectual property milestone, the disclosure emphasizes material strategic and commercial value: it strengthens ATH434's long-term commercial potential, enables future development in Parkinson's disease, supports potential partnerships, and represents \"one of the most critical steps\" in protecting the innovation behind the company's lead clinical asset. This is a material operational/strategic event affecting the registrant's competitive position and development prospects, though it does not fit the specific categories of M\u0026A, litigation, or regulatory approval.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-13T10:10:51.733702+00:00","company_name":"ALTERITY THERAPEUTICS LTD","ticker":"PRNAF","filing_date":"2026-08-13"}]}